What is Zacks Research's Estimate for TMO Q2 Earnings?

Key Points

• Zacks Research revised its Q2 2026 earnings estimate for Thermo Fisher Scientific, lowering it from $6.94 to $6.01 per share.
• The consensus estimate for Thermo Fisher's full-year earnings stands at $23.28 per share, with analysts also providing estimates for Q1 2027 at $6.26 EPS and FY2027 at $27.17 EPS.
• Thermo Fisher Scientific's stock is rated as a "Moderate Buy" with an average price target of $593.00, and insiders have recently sold significant amounts of company stock.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Zacks Research dropped their Q2 2026 earnings estimates for shares of Thermo Fisher Scientific in a note issued to investors on Wednesday, August 13th. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $6.01 per share for the quarter, down from their prior forecast of $6.94. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's FY2026 earnings at $24.21 EPS, Q1 2027 earnings at $6.26 EPS and FY2027 earnings at $27.17 EPS.

A number of other equities analysts also recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Barclays lifted their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Up 0.5%

NYSE:TMO traded up $2.65 during trading hours on Friday, hitting $487.69. 464,117 shares of the company's stock traded hands, compared to its average volume of 2,484,263. The firm has a market cap of $184.16 billion, a P/E ratio of 28.21, a P/E/G ratio of 2.59 and a beta of 0.74. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock's fifty day moving average price is $433.08 and its two-hundred day moving average price is $461.44.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the company earned $5.37 EPS. The business's revenue for the quarter was up 2.9% compared to the same quarter last year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock valued at $8,345,792 over the last quarter. Corporate insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $30,000. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific in the first quarter valued at $30,000. Finally, Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at $31,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.